Koninklijke Philips N.V. (PHG)

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

February 19, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips' Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

February 12, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality imaging for clinicians.

PHG swings to Q4 profit as comparable sales jump 7% and orders rise, but shares fall despite double-digit EBITA growth and 2026 outlook.

February 11, 2026 Co-funded by the EU's Innovative Health Initiative (IHI), the research consortium is coordinated by Philips, together with Erasmus MC as academic lead, and will combine advanced medical imaging and minimally invasive techniques to transform treatment of bleeding and tumors in the brain Five-year research program with total budget of EUR 38.4 million includes eight clinical studies to validate technical solutions for minimally invasive neurosurgery Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the SEISMIC research consortium, coordinated by Philips, together with Erasmus MC as academic lead, has been awarded funding from the Innovative Health Initiative (IHI) to transform neurosurgery through the seamless integration of minimally invasive surgical techniques and advanced imaging technologies. The EUR 23.5 million public funding will be complemented by EUR 14.9 million in in-kind contributions and additional resources from industry partners, supporting a five-year research and innovation program that also includes eight clinical studies.

ABC Arbitrage SA decreased its holdings in Koninklijke Philips N.V. (NYSE: PHG) by 79.1% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 50,362 shares of the technology company's stock after selling 190,099 shares during the quarter. ABC Arbitrage SA's holdings in Koninklijke

Koninklijke Philips N.V. (PHG) Q4 2025 Earnings Call Transcript

US stock futures down, major companies reporting Q3 earnings today: Coca-Cola, Credo Tech, CVS Health, Philips, Ford.

Roy Jakobs has headed Philips since October 2022 and the company said it would put his re-appointment to shareholders later this year.

Amsterdam, February 10, 2026 Full year and Q4 highlights Comparable order intake growth 6% in 2025; up 7% in Q4 Group sales of EUR 17.8 billion in 2025, EUR 5.1 billion in Q4; comparable sales growth 2% in 2025, 7% in Q4 Income from operations was EUR 1,424 million in 2025; EUR 540 million in Q4 Adjusted EBITA margin increased 80 basis points to 12.3% of sales in 2025; up 160 basis points to 15.1% in Q4 Operating cash flow of EUR 1,172 million in 2025; EUR 1,391 million in Q4 Free cash flow of EUR 512 million in 2025; EUR 1,200 million in Q4 Productivity savings of EUR 0.8 billion in 2025; delivered 2023-2025 target of EUR 2.5 billion Proposed 2025 dividend of EUR 0.85 per share, in shares or cash at the option of the shareholder Outlook for 2026 published Capital Markets Day Philips sets out plan to drive profitable growth to deliver sustainable value, including new, integrated 2030 Impact Ambitions. Plan comprises three pillars: segment-specific growth strategies, innovation as a key growth driver and continued disciplined execution Philips publishes 2026-2028 financial targets, including mid-single-digit comparable sales growth CAGR over the period and mid-teens Adjusted EBITA margin in 2028 Roy Jakobs, CEO of Royal Philips: “In 2025, we delivered on our commitments as we scaled better care for more people.

February 10, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Roy Jakobs is proposed to be re-appointed as its President/Chief Executive Officer and member of the Board of Management. The decision to propose the re-appointment of Roy Jakobs reflects the Supervisory Board's recognition of the progress made since 2022 and its confidence in his leadership as Philips enters the next phase of driving profitable growth.

Shares of Koninklijke Philips N.V. (NYSE: PHG - Get Free Report) have received a consensus rating of "Hold" from the six brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have assigned a buy recommendation to

February 3, 2026 Co-funded by the EU's Innovative Health Initiative (IHI), the Philips-coordinated research consortium will combine advanced medical imaging, robotic guidance technologies, and AI to standardize and enhance the precision of minimally invasive cancer treatments Five-year research program with total budget of EUR 23.9 million includes five clinical studies to validate the technical solutions, with the aim of setting a new benchmark for precision, safety, and efficiency in minimally invasive cancer care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the PreciseOnco consortium, coordinated by Philips, has been awarded funding from the EU's Innovative Health Initiative (IHI) to advance precision cancer treatment through the integration of advanced medical imaging, robotic assistance, and minimally invasive therapies. The EUR 14.9 million public funding will be complemented by EUR 9 million in in-kind contributions and additional resources from industry partners, supporting a five-year research and innovation program that also includes five clinical studies.

Philips is recognized for its market-leading innovation and comprehensive digital pathology ecosystem, driving global transformation in diagnostics and healthcare informatics SAN ANTONIO, Jan. 29, 2026 /PRNewswire/ -- Frost & Sullivan  is pleased to announce that Philips  has been awarded the 2025 Global Enabling Technology Leadership Recognition in the Digital Pathology–Healthcare Informatics sector for its outstanding achievements in delivering next-generation digital pathology innovation, accelerated workflow modernization, and clinical informatics. This recognition highlights Philips Healthcare's consistent leadership in driving measurable outcomes, strengthening its global market presence, and delivering customer-centric innovation in an increasingly complex healthcare environment.

Philips benefits from sector-wide valuation tailwinds, anticipated MedTech revival in 2026, and accelerating organic revenue growth. AI integration, highlighted by the SpectraWAVE acquisition, is set to drive higher growth, margin expansion, and capital efficiency for PHG. European healthcare has lagged for three years, leaving valuations attractive; we expect 2026 to mark a re-engagement phase for generalists and a healthier backdrop for the sector.